Influence of ivabradine on reverse remodelling during mechanical unloading

Cardiovascular Research

Volumn 97, Issue 2, 2013, Pages 230-239

  Navaratnarajah, Manoraj ^a   Ibrahim, Michael ^a   Siedlecka, Urszula ^a   Van Doorn, Carin ^b   Shah, Adarsh ^a   Gandhi, Ajay ^a   Dias, Priyanthi ^a   Sarathchandra, Padmini ^a   Yacoub, Magdi H ^a   Terracciano, Cesare M ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cardiovascular surgery; Heart failure; Heart rate; Reverse remodelling; Ventricular assist device

Indexed keywords

CALCIUM CHANNEL L TYPE; CALCIUM ION; IVABRADINE; METOPROLOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM CURRENT; CELL FUNCTION; CELL SIZE; CELL STRUCTURE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; EXCITATION CONTRACTION COUPLING; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE SIZE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HEART WORK; HETEROTOPIC TRANSPLANTATION; MALE; MECHANICAL UNLOADING; NONHUMAN; PRIORITY JOURNAL; RAT; SARCOPLASMIC RETICULUM; TRANSVERSE TUBULAR SYSTEM;

ANIMALS; ATROPHY; BENZAZEPINES; CALCIUM; CALCIUM CHANNELS, L-TYPE; EXCITATION CONTRACTION COUPLING; FIBROSIS; HEART FAILURE; HEART RATE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; METOPROLOL; MYOCARDIUM; RATS; VENTRICULAR REMODELING;

EID: 84872566987     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs318     Document Type: Article

References (60)

1. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA et al. Third INTERMACS Annual Report: the evolution of destination therapy in the United States. J Heart Lung Transplant 2011;30:115-123.
2. Mancini DM, Beniaminovitz A, Levin H, Catanese K, Flannery M, DiTullio M et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation 1998;98:2383-2389.
3. Simon MA, Kormos RL, Murali S, Nair P, Heffernan M, Gorcsan J et al. Myocardial recovery using ventricular assist devices: prevalence, clinical characteristics, and outcomes. Circulation 2005;112:I32-I36.
4. Klotz S, Jan Danser AH, Burkhoff D. Impact of left ventricular assist device (LVAD) support on the cardiac reverse remodeling process. Prog Biophys Mol Biol 2008;97: 479-496.
5. Yacoub MH, Tansley P, Birks EJ, Banner NR, Khaghani A, Bowles C. A novel combination therapy to reverse end-stage heart failure. Transplant Proc 2001;33:2762-2764.
6. Klotz S, Burkhoff D, Garrelds IM, Boomsma F, Danser AH. The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences? Eur Heart J 2009; 30:805-812.
7. Ito K, Nakayama M, Hasan F, Yan X, Schneider MD, Lorell BH. Contractile reserve and calcium regulation are depressed in myocytes from chronically unloaded hearts. Circulation 2003;107:1176-1182.
8. Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006;355: 1873-1884.
9. Birks EJ, George RS, Hedger M, Bahrami T, Wilton P, Bowles CT et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation 2011;123:381-390.
10. Klotz S, Danser AH, Foronjy RF, Oz MC, Wang J, Mancini D et al. The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. J Am Coll Cardiol 2007;49:1166-1174.
11. Matsumiya G, Monta O, Fukushima N, Sawa Y, Funatsu T, Toda K et al. Who would be a candidate for bridge to recovery during prolonged mechanical left ventricular support in idiopathic dilated cardiomyopathy? J Thorac Cardiovasc Surg 2005;130: 699-704.
12. Bois P, Bescond J, Renaudon B, Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 1996;118: 1051-1057.
13. Riccioni G. Ivabradine: recent and potential applications in clinical practice. Expert Opin Pharmacother 2011;12:443-450.
14. Tardif JC, O'Meara E, Komajda M, Bohm M, Borer JS, Ford I et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 2011;32:2507-2515.
15. Doesch AO, Ammon K, Konstandin M, Celik S, Kristen A, Frankenstein L et al. Heart rate reduction for 12 months with ivabradine reduces left ventricular mass in cardiac allograft recipients. Transplantation 2009;88:835-841.
16. Zhang R, Haverich A, Struber M, Simon A, Pichlmaier M, Bara C. Effects of ivabradine on allograft function and exercise performance in heart transplant recipients with permanent sinus tachycardia. Clin Res Cardiol 2008;97:811-819.
17. Maczewski M, Mackiewicz U. Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart. Cardiovasc Res 2008;79:42-51.
18. Milliez P, Messaoudi S, Nehme J, Rodriguez C, Samuel JL, Delcayre C. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am J Physiol Heart Circ Physiol 2009;296: H435-H441.
19. Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004;109:1674-1679.
20. Ceconi C, Comini L, Suffredini S, Stillitano F, Bouly M, Cerbai E et al. Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. Am J Physiol Heart Circ Physiol 2011;300:H366-H373.
21. Fang Y, Debunne M, Vercauteren M, Brakenhielm E, Richard V, Lallemand F et al. Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia. J Cardiovasc Pharmacol 2011;59: 260-267.
22. Dedkov EI, Zheng W, Christensen LP, Weiss RM, Mahlberg-Gaudin F, Tomanek RJ. Preservation of coronary reserve by ivabradine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagen. Am J Physiol Heart Circ Physiol 2007;293:H590-H598.
23. Soppa GK, Lee J, Stagg MA, Felkin LE, Barton PJ, Siedlecka U et al. Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure. Cardiovasc Res 2008;77:695-706.
24. Oriyanhan W, Tsuneyoshi H, Nishina T, Matsuoka S, Ikeda T, Komeda M. Determination of optimal duration of mechanical unloading for failing hearts to achieve bridge to recovery in a rat heterotopic heart transplantation model. J Heart Lung Transplant 2007;26:16-23.
25. Korecky B, Masika M. Use of heterotopically isotransplanted rat heart to study the effect of load on cardiac mass. J Cardiovasc Pharmacol 1991;17(Suppl 2):S105.
26. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99: 2694-2701.
27. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;89:2273-2282.
28. Ibrahim M, Al MA, Navaratnarajah M, Siedlecka U, Soppa GK, Moshkov A et al. Prolonged mechanical unloading affects cardiomyocyte excitation-contraction coupling, transverse-tubule structure, and the cell surface. FASEB J 2010;24:3321-3329.
29. Bers DM. Altered cardiac myocyte Ca regulation in heart failure. Physiology (Bethesda) 2006;21:380-387.
30. Song LS, Sobie EA, McCulle S, Lederer WJ, Balke CW, Cheng H. Orphaned ryanodine receptors in the failing heart. Proc Natl Acad Sci USA 2006;103:4305-4310.
31. Fang Y, Nicol L, Harouki N, Monteil C, Wecker D, Debunne M et al. Improvement of left ventricular diastolic function induced by beta-blockade: a comparison between nebivolol and metoprolol. J Mol Cell Cardiol 2011;51:168-176.
32. Sun T, Shen LH, Chen H, Li HW, Guo CY, Li ZZ et al. Effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi 2008;36:68-71.
33. Morita H, Suzuki G, Mishima T, Chaudhry PA, Anagnostopoulos PV, Tanhehco EJ et al. Effects of long-term monotherapy with metoprolol CR/XL on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Cardiovasc Drugs Ther 2002;16:443-449.
34. Seeland U, Schaffer A, Selejan S, Hohl M, Reil JC, Muller P et al. Effects of AT1-and beta-adrenergic receptor antagonists on TGF-beta1-induced fibrosis in transgenic mice. Eur J Clin Invest 2009;39:851-859.
35. Wei S, Chow LT, Sanderson JE. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. J Am Coll Cardiol 2000;36:276-281.
36. Saito S, Matsumiya G, Sakaguchi T, Miyagawa S, Yamauchi T, Kuratani T et al. Cardiac fibrosis and cellular hypertrophy decrease the degree of reverse remodeling and improvement in cardiac function during left ventricular assist. J Heart Lung Transplant 2010;29:672-679.
37. Klotz S, Foronjy RF, Dickstein ML, Gu A, Garrelds IM, Danser AH et al. Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. Circulation 2005;112:364-374.
38. Rodrigue-Way A, Burkhoff D, Geesaman BJ, Golden S, Xu J, Pollman MJ et al. Sarcomeric genes involved in reverse remodeling of the heart during left ventricular assist device support. J Heart Lung Transplant 2005;24:73-80.
39. Bruckner BA, Stetson SJ, Perez-Verdia A, Youker KA, Radovancevic B, Connelly JH et al. Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support. J Heart Lung Transplant 2001;20:457-464.
40. Maybaum S, Mancini D, Xydas S, Starling RC, Aaronson K, Pagani FD et al. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation 2007;115:2497-2505.
41. Bruggink AH, van Oosterhout MF, De JN, Ivangh B, van Kuik J, Voorbij RH et al. Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. J Heart Lung Transplant 2006;25:1091-1098.
42. Bruckner BA, Stetson SJ, Farmer JA, Radovancevic B, Frazier OH, Noon GP et al. The implications for cardiac recovery of left ventricular assist device support on myocardial collagen content. Am J Surg 2000;180:498-501.
43. Delgado R III, Radovancevic B, Massin EK, Frazier OH, Benedict C. Neurohormonal changes after implantation of a left ventricular assist system. ASAIO J 1998;44: 299-302.
44. Cerbai E, Mugelli A. I(f) in non-pacemaker cells: role and pharmacological implications. Pharmacol Res 2006;53:416-423.
45. Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation 1998;97:2316-2322.
46. Terracciano CM, Hardy J, Birks EJ, Khaghani A, Banner NR, Yacoub MH. Clinical recovery from end-stage heart failure using left-ventricular assist device and pharmacological therapy correlates with increased sarcoplasmic reticulum calcium content but not with regression of cellular hypertrophy. Circulation 2004;109:2263-2265.
47. Heerdt PM, Holmes JW, Cai B, Barbone A, Madigan JD, Reiken S et al. Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure. Circulation 2000;102:2713-2719.
48. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 2000;101:365-376.
49. Altemose GT, Gritsus V, Jeevanandam V, Goldman B, Margulies KB. Altered myocardial phenotype after mechanical support in human beings with advanced cardiomyopathy. J Heart Lung Transplant 1997;16:765-773.
50. Drakos SG, Kfoury AG, Hammond EH, Reid BB, Revelo MP, Rasmusson BY et al. Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart. J Am Coll Cardiol 2010;56:382-391.
51. Galinanes M, Zhai X, Hearse DJ. The effect of load on atrophy, myosin isoform shifts and contractile function: studies in a novel rat heart transplant preparation. J Mol Cell Cardiol 1995;27:407-417.
52. Wang J, Marui A, Ikeda T, Komeda M. Partial left ventricular unloading reverses contractile dysfunction and helps recover gene expressions in failing rat hearts. Interact Cardiovasc Thorac Surg 2008;7:27-31.
53. Mizuno T,Weisel RD, Li RK. Reloading the heart: a new animal model of left ventricular assist device removal. J Thorac Cardiovasc Surg 2005;130:99-106.
54. Xydas S, Kherani AR, Chang JS, Klotz S, Hay I, Mutrie CJ et al. beta(2)-Adrenergic stimulation attenuates left ventricular remodeling, decreases apoptosis, and improves calcium homeostasis in a rodent model of ischemic cardiomyopathy. J Pharmacol Exp Ther 2006;317:553-561.
55. Wu YL, Ye Q, Sato K, Foley LM, Hitchens TK, Ho C. Noninvasive evaluation of cardiac allograft rejection by cellular and functional cardiac magnetic resonance. JACC Cardiovasc Imaging 2009;2:731-741.
56. Mangoni ME, Nargeot J. Genesis and regulation of the heart automaticity. Physiol Rev 2008;88:919-982.
57. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol 2008;153: 1589-1601.
58. Colin P, Ghaleh B, Monnet X, Hittinger L, Berdeaux A. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther 2004;308:236-240.
59. Christensen LP, Zhang RL, Zheng W, Campanelli JJ, Dedkov EI, Weiss RM et al. Postmyocardial infarction remodeling and coronary reserve: effects of ivabradine and beta blockade therapy. Am J Physiol Heart Circ Physiol 2009;297:H322-H330.
60. Heusch G, Skyschally A, Gres P, van Caster P, Schilawa D, Schulz R. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J 2008;29:2265-2275.